Peramivir: an intravenous neuraminidase inhibitor

Bibliography

• Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA 2004;11(292):1333-40
   Web of Science ®Google Scholar
• Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;2(289):179-86
   Web of Science ®Google Scholar
• Thompson WW, Weintraub E, Dhankhar P, et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir Viruses 2009;1(3):37-49
   Web of Science ®Google Scholar
• Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009;361(20):1935-44
   PubMed Web of Science ®Google Scholar
• Dawood FS, Jain S, Finelli L, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009;25(360):2605-15
   Google Scholar
• Babcock HM, Merz LR, Dubberke ER, Fraser VJ. Case-control study of clinical features of influenza in hospitalized patients. Infect Control Hosp Epidemiol 2008;10(29):921-6
   Web of Science ®Google Scholar
• Falsey AR, Murata Y, Walsh EE. Impact of rapid diagnosis on management of adults hospitalized with influenza. Arch Intern Med 2007;4(167):354-60
   Google Scholar
• Ison MG. Influenza in hospitalized adults: gaining insight into a significant problem. J Infect Dis 2009;4(200):485-8
   Web of Science ®Google Scholar
• Ison MG, Gnann JWJr, Nagy-Agren S, et al. Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza. Antivir Ther 2003;3(8):183-90
   Google Scholar
• Kaiser L, Wat C, Mills T, et al. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med 2003;14(163):1667-72
   Web of Science ®Google Scholar
• Lee N, Chan KS, Hui DSC, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009;4(200):492-500
   Web of Science ®Google Scholar
• Lee N, Chan PK, Choi KW, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007;4(12):501-8
   Google Scholar
• Leekha S, Zitterkopf NL, Espy MJ, et al. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007;9(28):1071-6
   Web of Science ®Google Scholar
• McGeer A, Green KA, Plevneshi A, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario. Canada. Clin Infect Dis 2007;12(45):1568-75
   Web of Science ®Google Scholar
• Murata Y, Walsh EE, Falsey AR. Pulmonary complications of interpandemic influenza A in hospitalized adults. J Infect Dis 2007;7(195):1029-37
   Web of Science ®Google Scholar
• Kumar A, Zarychanski R, Pinto R, et al. Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009;17(302):1872-9
   Google Scholar
• Davies A, Jones D, Bailey M, et al. Extracorporeal membrane oxygenation for 2009 influenza A (H1N1) acute respiratory distress syndrome. JAMA 2009;17(302):1888-95
   Google Scholar
• Webb SA, Pettila V, Seppelt I, et al. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009;20(361):1925-34
   Google Scholar
• GlaxoSmithKline. Relenza inhalation powder must not be nebulized. healthcare provider letter. 2009. Available from: http://www.fda.gov/downloads/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/UCM186224.pdf [Last accessed on 11 March 2015]
   Google Scholar
• Chand P, Kotian PL, Dehghani A, et al. Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity. J Med Chem 2001;25(44):4379-92
   Web of Science ®Google Scholar
• Taylor NR, von Itzstein M. Molecular modeling studies on ligand binding to sialidase from influenza virus and the mechanism of catalysis. J Med Chem 1994;5(37):616-24
   Web of Science ®Google Scholar
• Bossart-Whitaker P, Carson M, Babu YS, et al. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J Mol Biol 1993;4(232):1069-83
   Web of Science ®Google Scholar
• Babu YS, Chand P, Bantia S, et al. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J Med Chem 2000;19(43):3482-6
   Web of Science ®Google Scholar
• Bantia S, Parker CD, Ananth SL, et al. Comparison of the anti-influenza virus activity of RWJ-270201 with those of oseltamivir and zanamivir. Antimicrob Agents Chemother 2001;4(45):1162-7
   Web of Science ®Google Scholar
• Govorkova EA, Leneva IA, Goloubeva OG, et al. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001;10(45):2723-32
   Web of Science ®Google Scholar
• Kati WM, Montgomery D, Carrick R, et al. In vitro characterization of A-315675, a highly potent inhibitor of A and B strain influenza virus neuraminidases and influenza virus replication. Antimicrob Agents Chemother 2002;4(46):1014-21
   Web of Science ®Google Scholar
• Bantia S, Arnold CS, Parker CD, et al. Anti-influenza virus activity of peramivir in mice with single intramuscular injection. Antiviral Res 2006;1(69):39-45
   Web of Science ®Google Scholar
• Matrosovich M, Matrosovich T, Carr J, et al. Overexpression of the alpha-2,6-sialyltransferase in MDCK cells increases influenza virus sensitivity to neuraminidase inhibitors. J Virol 2003;15(77):8418-25
   Web of Science ®Google Scholar
• Cao RY, Xiao JH, Cao B, et al. Inhibition of novel reassortant avian influenza H7N9 virus infection in vitro with three antiviral drugs, oseltamivir, peramivir and favipiravir. Antivir Chem Chemother 2014;6(23):237-40
   Google Scholar
• Hurt AC, Selleck P, Komadina N, et al. Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes. Antiviral Res 2007;3(73):228-31
   Web of Science ®Google Scholar
• Stoner TD, Krauss S, DuBois RM, et al. Antiviral susceptibility of avian and swine influenza virus of the N1 neuraminidase subtype. J Virol 2010;19(84):9800-9
   Web of Science ®Google Scholar
• Boltz DA, Ilyushina NA, Arnold CS, et al. Intramuscularly administered neuraminidase inhibitor peramivir is effective against lethal H5N1 influenza virus in mice. Antiviral Res 2008;2(80):150-7
   Web of Science ®Google Scholar
• Drusano GL, Preston SL, Smee D, et al. Pharmacodynamic evaluation of RWJ-270201, a novel neuraminidase inhibitor, in a lethal murine model of influenza predicts efficacy for once-daily dosing. Antimicrob Agents Chemother 2001;7(45):2115-18
   Web of Science ®Google Scholar
• Sidwell RW, Bailey KW, Morrey JD, et al. Inhibition of influenza virus infections in immunosuppressed mice with orally administered peramivir (BCX-1812). Antiviral Res 2003;1(60):17-25
   Web of Science ®Google Scholar
• Sidwell RW, Smee DF, Huffman JH, et al. Influence of virus strain, challenge dose, and time of therapy initiation on the in vivo influenza inhibitory effects of RWJ-270201. Antiviral Res 2001;3(51):179-87
   Web of Science ®Google Scholar
• Sweet C, Jakeman KJ, Bush K, et al. Oral administration of cyclopentane neuraminidase inhibitors protects ferrets against influenza virus infection. Antimicrob Agents Chemother 2002;4(46):996-1004
   Web of Science ®Google Scholar
• Yun NE, Linde NS, Zacks MA, et al. Injectable peramivir mitigates disease and promotes survival in ferrets and mice infected with the highly virulent influenza virus, A/Vietnam/1203/04 (H5N1). Virology 2008;1(374):198-209
   Web of Science ®Google Scholar
• Sidwell RW, Smee DF, Huffman JH, et al. In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201. Antimicrob Agents Chemother 2001;3(45):749-57
   Web of Science ®Google Scholar
• Sidwell RW, Smee DF. Peramivir (BCX-1812, RWJ-270201): potential new therapy for influenza. Expert Opin Investig Drugs 2002;6(11):859-69
   Google Scholar
• Hai R, Schmolke M, Leyva-Grado VH, et al. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat Commun 2013;4:2854
   PubMed Web of Science ®Google Scholar
• Kitano M, Itoh Y, Ishigaki H, et al. Efficacy of repeated intravenous administration of peramivir against highly pathogenic avian influenza A (H5N1) virus in cynomolgus macaques. Antimicrob Agents Chemother 2014;8(58):4795-803
   Web of Science ®Google Scholar
• Young D, Fowler C, Bush K. RWJ-270201 (BCX-1812): a novel neuraminidase inhibitor for influenza. Philos Trans R Soc Lond B Biol Sci 2001;1416(356):1905-13
   Google Scholar
• Barroso L, Treanor J, Gubareva L, Hayden FG. Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther 2005;8(10):901-10
   Google Scholar
• Whitley R, Laughlin A, Carson S, et al. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials. Antivir Ther 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• BioCryst Pharmaceuticals, Inc Press Release. BioCryst provides peramivir update and reports first quarter 2009 financial results. 2009. Available from: http://www.prnewswire.com/news-releases/biocryst-provides-peramivir-update-and-reports-first-quarter-2009-financial-results-61796982.html [Last accessed on 12 March 2015]
   Google Scholar
• Kohno S, Kida H, Mizuguchi M, Shimada J. S-021812 Clinical Study Group. A double-blind, placebo-controlled study of intravenous peramivir in acute influenza patients. IDSA-ICAAC Annual Meeting 2008;Abstract V-4154a. "Conference Paper"
   Google Scholar
• Kohno S, Yen MY, Cheong HJ, et al. Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection. Antimicrob Agents Chemother 2011;11(55):5267-76
   Web of Science ®Google Scholar
• Takemoto Y, Asai T, Ikezoe I, et al. Clinical effects of oseltamivir, zanamivir, laninamivir and peramivir on seasonal influenza infection in outpatients in Japan during the winter of 2012-2013. Chemotherapy 2013;5(59):373-8
   Google Scholar
• Kohno S, Kida H, Mizuguchi M, et al. Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients. Antimicrob Agents Chemother 2011;6(55):2803-12
   Web of Science ®Google Scholar
• Ison MG, Mcgeer AJ, Hui DS, et al. Safety and efficacy of multiple-day treatment with intravenous peramivir or oral oseltamivir in hospitalized adults with acute influenza. XI International Symposium on Respiratory Viral Infections 2009; “Conference Paper”.
   Google Scholar
• de Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis 2014;12(59):e172-85
   Web of Science ®Google Scholar
• Ison MG. Optimizing antiviral therapy for influenza: understanding the evidence. Expert Rev Anti Infect Ther 2015;4(13):417-25
   Google Scholar
• Martin-Loeches I, Diaz E, Vidaur L, et al. Pandemic and post-pandemic influenza A (H1N1) infection in critically ill patients. Crit Care 2011;6(15):R286
   Web of Science ®Google Scholar
• Louie JK, Yang S, Acosta M, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 2012;9(55):1198-204
   Web of Science ®Google Scholar
• Food and Drug Administration. Emergency use authorization of peramivir IV fact sheet for health care providers. 2009. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf [Last accessed on 12 March 2015]
   Google Scholar
• Hayashi K, Iwasa K, Morinaga A, et al. Exacerbation of myasthenia gravis by intravenous peramivir. Muscle Nerve 2015;51(6):935-6
   PubMed Web of Science ®Google Scholar
• Harada-Shirado K, Ikeda K, Furukawa M, et al. Severe immune thrombocytopenia possibly elicited by the anti-influenza viral agent peramivir. Intern Med 2014;20(53):2369-71
   Web of Science ®Google Scholar
• Gao HN, Lu HZ, Cao B, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013;24(368):2277-85
   Web of Science ®Google Scholar
• Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013;9885(381):2273-9
   Web of Science ®Google Scholar
• Marjuki H, Mishin VP, Chesnokov AP, et al. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan. J Infect Dis 2015;2(211):249-57
   Web of Science ®Google Scholar
• Tang X, He H, Sun B, et al. ARDS associated with pneumonia caused by avian influenza A H7N9 virus treated with extracorporeal membrane oxygenation. Clin Respir J 2014. [Epub ahead of print]
   Google Scholar
• Yang ZF, Mok CK, Liu XQ, et al. Clinical, Virological and Immunological Features from Patients Infected with Re-Emergent Avian-Origin Human H7N9 Influenza Disease of Varying Severity in Guangdong Province. PLoS One 2015;2(10):e0117846
   Google Scholar
• Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): A pediatric drug use investigation. J Infect Chemother 2015;3(21):194-201
   Web of Science ®Google Scholar
• Sugaya N, Kohno S, Ishibashi T, et al. Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection. Antimicrob Agents Chemother 2012;1(56):369-77
   Web of Science ®Google Scholar
• Scheetz MH, Griffith MM, Ghossein C, et al. Pharmacokinetic assessment of peramivir in a hospitalized adult undergoing continuous venovenous hemofiltration. Ann Pharmacother 2011;12(45):e64
   Google Scholar
• Bentley ML, Hollistera AS, Hansenb AC, et al. Peramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemic. Int J Clin Pharmacol Ther 2014;12(52):1105-11
   Web of Science ®Google Scholar
• Ison MG. Anti-influenza therapy: The emerging challenge of resistance. Therapy 2009;6(6):883-91
   Google Scholar
• Meijer A, Rebelo-de-Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013. Antiviral Res 2014;110:31-41
   PubMed Web of Science ®Google Scholar
• Hurt AC, Ernest J, Deng YM, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009;1(83):90-3
   Web of Science ®Google Scholar
• Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005;11(49):4515-20
   Web of Science ®Google Scholar
• Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther 2006;8(11):971-6
   Google Scholar
• Memoli MJ, Hrabal RJ, Hassantoufighi A, et al. Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts. Clin Infect Dis 2010;9(50):1252-5
   Web of Science ®Google Scholar
• Abed Y, Simon P, Boivin G. Prophylactic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H274Y neuraminidase mutation. Antimicrob Agents Chemother 2010;7(54):2819-22
   Web of Science ®Google Scholar
• Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation. J Infect Chemother 2014;11(20):689-95
   Web of Science ®Google Scholar
• Birnkrant D, Cox E. The Emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009;361(23):2204-7
   PubMed Web of Science ®Google Scholar
• Rapivab (peramivir) [package insert]. BioCryst Pharmaceuticals Inc., Birmingham, AL; 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/206426lbl.pdf [Last accessed on 11 March 2015]
   Google Scholar
• Sleeman K, Guo Z, Barnes J, et al. R292K substitution and drug susceptibility of influenza A(H7N9) viruses. Emerg Infect Dis 2013;9(19):1521-4
   Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Summary Review of Peramivir. Application Number: 206426Orig1s000. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206426Orig1s000SumR.pdf [Last accessed on 11 March 2015]
   Google Scholar